AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30835255
Drug: De novo
RxNorm normalized name: sangre de grado
FDA approved: no
EMA approved: no
PMDA approved: no
Description: De novo synthesized neoantigen-loaded dendritic cell vaccines
Trial: 30835255
Drug: Personalized immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized immunotherapy
Trial: 30836948
Drug: Dialysate calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dialysate calcium concentration > 2.5 mEq/L
Trial: 30836948
Drug: Intravenous potassium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous potassium and weight change
Trial: 30839493
Drug: Systemic hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic hormone therapy (HT) prescriptions
Trial: 30839493
Drug: New prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New prescriptions for systemic HT
Trial: 30839493
Drug: Renewal prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renewal prescriptions for systemic HT
Trial: 30839493
Drug: Renewal prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renewal prescriptions with conjugated equine estrogen doses ≥0.625 mg
Trial: 30839493
Drug: Prescriptions for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions for systemic estrogen in women with a uterus
Trial: 30840757
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D treatment (4000 units daily for 2 weeks)
Trial: 30840787
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg) for 8 weeks (Phase 1)
Trial: 30840787
Drug: Escitalopram (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10-20 mg) continued for responders, adjunctive aripiprazole (2-10 mg) for nonresponders for a further 8 weeks (Phase 2)
Trial: 30843107
Drug: Increased salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased salt iodine concentration from 20 to 25 mg/kg
Trial: 30843107
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (previous iodine concentration of 20 mg/kg)
Trial: 30843659
Drug: Ruxolitinib (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib (5, 10, 15, or 20 mg BID for 3 weeks out of five for seven cycles) combined with Ibrutinib (420 mg daily)
Trial: 30845873
Drug: Low- or
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low- or high-dose β-blockers
Trial: 30845997
Drug: Three servings
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three servings (28.3 g each) of sun dried raisins daily for 14 days
Trial: 30846500
Drug: Weekly subcutaneous
RxNorm normalized name: Weekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×10^9/L)
Trial: 30848695
Drug: Ciprofloxacin Dry
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin Dry Powder for Inhalation
Trial: 30849082
Drug: 5-hour oral
RxNorm normalized name: 3α-(diphenylmethoxy)-1αH,5αH-tropane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-hour oral glucose tolerance test to measure DI by OMM
Trial: 30850297
Drug: Endurant II/IIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endurant II/IIs endograft in conjunction with Heli-FX EndoAnchor implants (ESAR)
Trial: 30850381
Drug: Venetoclax plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax plus G-CHOP
Trial: 30850381
Drug: G-CHOP (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CHOP (control)
Trial: 30850562
Drug: Endostatin and
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endostatin and oxaliplatin (OHP) administered intravenously at doses of 7.5 mg/m², with radiotherapy delivered at a daily fraction of 2.0 Gy to a total dose of 60.0 Gy over 6 weeks.
Trial: 30852126
Drug: Risperidone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (mean dose 3.73 ± 1.72 mg) for 6 weeks
Trial: 30852546
Drug: Volatile organic
RxNorm normalized name: coal tar pitch volatiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volatile organic compounds (VOCs) evaluation using offline and online technologies including proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry, gas chromatography mass spectroscopy, and comprehensive two-dimensional gas chromatography-mass spectrometry.
Trial: 30854456
Drug: Spectroscopic MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectroscopic MRI (sMRI) integrated with standard imaging for radiation therapy planning
Trial: 30857532
Drug: Post-procedural glycemic
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-procedural glycemic variability (mean daily δ blood glucose during the first 2 days after TAVI, median value 4.3 mmol/l)
Trial: 30857780
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with a different antiviral regimen
Trial: 30857956
Drug: Pertuzumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously)
Trial: 30858218
Drug: DSM265 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSM265 at 400 mg
Trial: 30858985
Drug: Fish protein
RxNorm normalized name: Fish Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish protein supplementation (5.2 g daily for 6 weeks)
Trial: 30859424
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent blue dye injection
Trial: 30859504
Drug: Personalized trials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized trials of BP medications
Trial: 30859504
Drug: Renin-angiotensin system-blocking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renin-angiotensin system-blocking agents
Trial: 30859504
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of thiazide and beta-blocker
Trial: 30859504
Drug: Any of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any of three classes of BP medications
Trial: 30860484
Drug: Tablet app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablet app for the Simplified Gestational Age Score (T-SGAS) used by auxiliary nurse midwives to estimate GA status of newborns.
Trial: 30860945
Drug: Neratinib 240
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Neratinib 240 mg orally once per day plus capecitabine 750 mg/m²
Trial: 30862609
Drug: Palliative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative chemotherapy (platinum/pemetrexed)
Trial: 30862646
Drug: Isatuximab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab (5 mg/kg, 10 mg/kg, or 20 mg/kg)
Trial: 30862646
Drug: Isatuximab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isatuximab (10 mg/kg)
Trial: 30862650
Drug: Bluetooth-enabled insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bluetooth-enabled insulin pen caps
Trial: 30863020
Drug: Multicomponent intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multicomponent intervention (educational program for psychiatrists, collaborative care program for patients and relatives, reminder system using a medication reminder application)
Trial: 30863141
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment effect of methoxyflurane vs placebo
Trial: 30863450
Drug: Single treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single treatment (Control)
Trial: 30865002
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of opioids
Trial: 30865223
Drug: Molecular-based recommended
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular-based recommended therapies (MBRT)
Trial: 30865367
Drug: Heart failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart failure medications (including ACE-Is/ARBs, β-blockers, MRAs, digoxin, ivabradine, diuretics)
Trial: 30866657
Drug: nHDL <100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nHDL <100 mg/dL
Trial: 30866657
Drug: nHDL 100-129
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nHDL 100-129 mg/dL
Trial: 30866657
Drug: nHDL ≥130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nHDL ≥130 mg/dL
Trial: 30866657
Drug: LDL <70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL <70 mg/dL
Trial: 30866657
Drug: LDL 70-99
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL 70-99 mg/dL
Trial: 30866657
Drug: LDL ≥100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDL ≥100 mg/dL
Trial: 30866657
Drug: Triglyceride <84
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride <84 mg/dL
Trial: 30866657
Drug: Triglyceride 84-149
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride 84-149 mg/dL
Trial: 30866657
Drug: Triglyceride ≥150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride ≥150 mg/dL
Trial: 30866994
Drug: Coagulated blood
RxNorm normalized name: blood coagulation factor XIV
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulated blood from the patient as an alternative for ultrasound gel
Trial: 30867935
Drug: Safe Childbirth
RxNorm normalized name: Safe-Guard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safe Childbirth Checklist (SCC) program implemented in 19 intervention facilities with monthly supportive supervision and supply of drugs and equipment.
Trial: 30868475
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus PEMF therapy
Trial: 30868550
Drug: Tumor Necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor Necrosis Factor Inhibitors (TNFis)
Trial: 30869114
Drug: Early childhood
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early childhood protein intake (mean 58.3 g/d)
Trial: 30869127
Drug: artemether-lumefantrine treatment
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artemether-lumefantrine treatment
Trial: 30871493
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg Q2W) followed by nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W) after a 3-cycle run-in phase.
Trial: 30871493
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg Q2W) only for patients not escalated to ipilimumab.
Trial: 30872388
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg oral dose) in patients with mild hepatic impairment
Trial: 30872388
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg oral dose) in patients with moderate hepatic impairment
Trial: 30872388
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg oral dose) in patients with normal hepatic function
Trial: 30873290
Drug: Milk powder
RxNorm normalized name: Milk powder
DrugBank: Skim milk (DB15546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk powder supplemented with calcium and vitamin D and periodontal therapy (PT)
Trial: 30873290
Drug: Conventional periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional periodontal treatment and consumption of milk fortified with calcium-vitamin D
Trial: 30873623
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKA) ± antiplatelet (AP) therapy
Trial: 30873623
Drug: Non-VKA oral
RxNorm normalized name: Tavist Non-Sedating Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-VKA oral anticoagulant (NOAC) ± AP
Trial: 30875094
Drug: Fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 120 mg + Osimertinib 80 mg single dose on days 1 and 39 and Osimertinib 80 mg once daily from days 4 to 41
Trial: 30875094
Drug: Fexofenadine 120
RxNorm normalized name: fexofenadine hydrochloride 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine 120 mg + Osimertinib 80 mg at steady state
Trial: 30876442
Drug: Simultaneous integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin) at Maximum Tolerated Dose (MTD) of 59.92Gy/2.14Gy/28f
Trial: 30876442
Drug: Simultaneous integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy (paclitaxel and nedaplatin)
Trial: 30876442
Drug: Simultaneous integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous integrated boost (SIB) technique with elective nodal irradiation (ENI) and dual-drug chemotherapy
Trial: 30876444
Drug: dIMRT (dynamic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dIMRT (dynamic intensity-modulated radiation therapy)
Trial: 30876444
Drug: VMAT (volumetric-modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMAT (volumetric-modulated arc therapy)
Trial: 30877202
Drug: Tocilizumab (TCZ)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TCZ) therapy, administered via injections at weeks 0, 4, and 8
Trial: 30877569
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg single-dose
Trial: 30877569
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg twice daily
Trial: 30879979
Drug: qHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: qHPV vaccine (three doses on Day 1, Month 2, Month 6)
Trial: 30880554
Drug: Medical nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical nutrition therapy program
Trial: 30881452
Drug: Intramuscular neridronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular neridronate (25 mg IM once a month for 6 years)
Trial: 30881909
Drug: Fractionated-dose spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated-dose spinal anesthesia injection
Trial: 30881909
Drug: Single-dose spinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose spinal anesthesia injection
Trial: 30883662
Drug: AdV-tk at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdV-tk at doses of 1 × 10^11 and 3 × 10^11 vector particles (vp) injected into the tumor bed followed by 14 days of valacyclovir.
Trial: 30883662
Drug: AdV-tk at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdV-tk at dose level 2.
Trial: 30883668
Drug: Post-operative pain
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative pain treatment (various analgesic treatments used, including morphine)
Trial: 30883668
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine consumption
Trial: 30885222
Drug: Increased sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased sodium excretion and plasma sodium
Trial: 30885327
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus chemotherapy (carboplatin and etoposide)
Trial: 30885354
Drug: Radical consolidative
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical consolidative treatment (RCT)
Trial: 30886964
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg/day for 12 months
Trial: 30886990
Drug: Modified Pilates
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Pilates exercises, treated twice a week for eight weeks.
Trial: 30886990
Drug: Aerobic exercises
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercises on treadmills or stationary bikes, treated twice a week for eight weeks.
Trial: 30887180
Drug: Olaparib 300
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg (twice daily) as monotherapy
Trial: 30887180
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg (twice daily) as monotherapy
Trial: 30887180
Drug: Olaparib 100
RxNorm normalized name: olaparib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olaparib 100 mg (twice daily) in combination with paclitaxel (80 mg/m weekly)
Trial: 30887180
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (Olaparib + Paclitaxel)
Trial: 30887876
Drug: Guselkumab administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guselkumab administered with a novel patient-controlled injector (One-Press)
Trial: 30888111
Drug: Predictive model
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive model for risk of variceal bleeding comprising of grade 2-3 esophageal varices, red spots, and fibrinogen level <150 mg/dL
Trial: 30889492
Drug: Trifluridine/tipiracil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluridine/tipiracil at recommended dose (RD) of 35 mg/m² in combination with oxaliplatin
Trial: 30890162
Drug: Remotely supervised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remotely supervised transcranial direct current stimulation (RS-tDCS) administered daily (Monday - Friday) for a total of sixty sessions, 20 minutes of 2.5 mA direct current targeting the cerebellum, paired with cognitive training and physical exercises.
Trial: 30890544
Drug: Plerixafor (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plerixafor (240 µg/kg)
Trial: 30890548
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device, activated monthly before intravenous carboplatin chemotherapy.
Trial: 30890548
Drug: Low-intensity pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-intensity pulsed ultrasound (LIPU) using SonoCloud-1 device before carboplatin chemotherapy.
Trial: 30890600
Drug: Fludarabine, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) induction followed by 36 months of rituximab maintenance therapy
Trial: 30891607
Drug: Intradermal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal delivery of INO-4201
Trial: 30891607
Drug: Intramuscular delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular delivery of INO-4201
Trial: 30891607
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of INO-4201 and INO-4202 with interleukin-12
Trial: 30891607
Drug: Intradermal delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal delivery of INO-4202
Trial: 30891607
Drug: Intramuscular delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular delivery of INO-4202
Trial: 30892988
Drug: Venetoclax 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax 600 mg per day orally in 28-day cycles plus low-dose cytarabine (LDAC) 20 mg/m²
Trial: 30895237
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa 150 μg
Trial: 30895244
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL insemination volume